Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
El.En. SpAELEAF 73 3-Year EPS without NRI Growth Rate is -4.00% as of Mar. 2026. GuruFocus rates ELEAF with a GF Score™ of 73/100 and a GF Value™ of $13.50 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 656 Medical Devices & Instruments companies, El.En. SpA ranks worse than 67.23% on this metric.
During the past 12 months, El.En. SpA's average EPS without NRI Growth Rate was -9.70% per year.
During the past 3 years, the average EPS without NRI Growth Rate was -4.00% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 16.50% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 16.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of El.En. SpA was 189.00% per year. The lowest was -60.10% per year. And the median was 9.50% per year.
El.En. SpA (OTCPK:ELEAF) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
El.En. SpA 3-Year EPS without NRI Growth Rate Related Terms
ELEAF vs ABT, SYK, MDT: 3-Year EPS without NRI Growth Rate Comparison
For the Medical Devices subindustry, El.En. SpA's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
El.En. SpA 3-Year EPS without NRI Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, El.En. SpA's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where El.En. SpA's 3-Year EPS without NRI Growth Rate falls into.
El.En. SpA 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of -4.00% mean?
El.En. SpA (ELEAF) has a 3-Year EPS without NRI Growth Rate of -4.00% as of Mar. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for El.En. SpA and its competitors. According to the industry distribution chart, El.En. SpA ranks #441 out of 656 companies in the Medical Devices & Instruments industry, placing it in the top 67.2%.
Is El.En. SpA's 3-Year EPS without NRI Growth Rate too high?
El.En. SpA's current 3-Year EPS without NRI Growth Rate is -4.00%. Based on the distribution chart, El.En. SpA ranks #441 out of 656 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, El.En. SpA has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does El.En. SpA's 3-Year EPS without NRI Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, El.En. SpA ranks #441 out of 656 companies for 3-Year EPS without NRI Growth Rate. This places El.En. SpA in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 8.05. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EPS without NRI Growth Rate among Medical Devices & Instruments companies is 8.05, based on 656 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for El.En. SpA and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EPS without NRI Growth Rate is 8.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. El.En. SpA's current 3-Year EPS without NRI Growth Rate is -4.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is El.En. SpA stock overvalued right now?
Based on GuruFocus' analysis, El.En. SpA (ELEAF) is currently considered Modestly Overvalued. The stock's GF Value™ is $13.50, compared to a current price of $17.50 — trading 29.6% above its estimated fair value. The current 3-Year EPS without NRI Growth Rate is -4.00%. El.En. SpA's overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For El.En. SpA (ELEAF), the current 3-Year EPS without NRI Growth Rate is -4.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is El.En. SpA (ELEAF) Overvalued in 2026?
Based on GuruFocus' analysis, El.En. SpA stock appears to be overvalued.
The current stock price of $17.50 is trading 29.6% above its estimated GF Value™ of $13.50.
GuruFocus considers El.En. SpA to be Modestly Overvalued.
Key valuation signals for ELEAF:
3-Year EPS without NRI Growth Rate: -4.00%
GF Value™: $13.50 vs. price of $17.50 (29.6% above fair value)
No single metric tells the full story. See the ELEAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
El.En. SpA is engaged in the research and development, manufacturing, distribution, and sales of laser systems. The company operates in two divisions: medical and industrial. In the medical division, the application of laser is used as a healing treatment for aesthetic, surgical, physiotherapy and dental. Industrial division develops solutions for laser material processing applications through cutting, marking, laser sources and restoration. The company generates the majority of its revenue from the medical division. Geographically, it derives maximum revenue from the Rest of the World.
73GF Score
Get the complete analysis for ELEAF
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELEAF has been successfully added to your 
